Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gedeon Richter Pharma GmbH

http://www.gedeonrichter.de

Latest From Gedeon Richter Pharma GmbH

US And EU Approvals In First Half 2021 Underscore US-First Orientation Of Novel Drug Development

Close to 90% of the FDA’s 2021 first half novel approvals were cleared in the US before Europe, while the EU’s EMA acted first on only 15% of its first half marketing authorizations for new active substances. Exclusive Pink Sheet analysis explores use of expedited review schemes, special pathways and other comparative trends.

Approvals Review Pathway

Six Key Infectious Disease New Drug Launches To Look Out For In 2022

In a series on articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are six new anti-infectives expected to reach the market for the first time next year, all with an above average likelihood of approval.

Companies Approvals

Richter And Mithra Extend Estelle To Latin America

Gedeon Richter and Mithra have expanded their partnership on an in-development contraceptive, Estelle, to cover several Latin American territories on top of Europe and Russia.

Deals Value-Added Medicines
See All

Company Information

UsernamePublicRestriction

Register